Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-03-01
1997-04-15
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514253, 514269, 544238, 544242, 544243, 544336, 544337, 546 77, A61K 3145, C07D22102
Patent
active
056209860
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention is directed to novel urea, thiourea, thiocarbamyl and carbamyl 4-azasteroidal 5-alpha-reductase inhibitors.
The art reveals that certain undesirable physiological manifestations, such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness and benign prostatic hypertrophy, art the result of hyperandrogenic stimulation caused by an excessive accumulation of testosterone or similar androgenic hormones in the metabolic system. Early attempts to provide a chemotherapeutic agent to counter the undesirable results of hyperandrogenicity resulted in the discovery of several steroidal antiandrogens having undesirable hormonal activities of their own. The estrogens, for example, not only counteract the effect of the androgens but have a feminizing effect as well. Non-steroidal antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethyl-isobutyranilide. See Neri, et al., Endo., Vol. 91, No. 2 (1972). However, these products, though devoid of hormonal effects, are peripherally active, competing with the natural androgens for receptor sites, and hence have a tendency to feminize a male host or the male fetus of a female host
It is now known in the art that the principal mediator of androgenic activity in some target organs is 5.alpha.-dihydrotestosterone, and that it is formed locally in the target organ by the action of testosterone-5.alpha.-reductase. It is also known that inhibitors of testosterone-5.alpha.-reductase will serve to prevent or lessen symptoms of hyperandrogenic stimulation. A number of 4-aza steroid compounds are known in the art that are 5.alpha.-reductase inhibitors. For example, see U.S. Pat. Nos. 2,227,876, 3,239,417, 3,264,301 and 3,285,918; French Patent No. 1,465,544; Doorenbos and Solomons, J. Pharm. Sci. 62, 4, pp. 638-640 (1973); Doorenbos and Brown, J..Pharm. Sci., 60, 8, pp. 1234-1235 (1971); and Doorenbos and Kim, J. Pharm. Sci. 63, 4, pp. 620-622 (1974).
In addition. U.S. Pat. Nos. 4,377,584, 4,220,775, 4,859,681, 4,760,071 and the articles J. Med. Chem. 27, p. 1690-1701 (1984) and J. Med. Chem. 29, 2998-2315 (1986) of Rasmusson, et al., U.S. Pat. No. 4,845,104 to Carlin, et al., and U.S. Pat. No. 4,732,897 to Cainelli, et al. describe 4-aza-17.beta.-substituted-5.alpha.-androstan-3-ones which are said to be useful in the treatment of DHT-related hyperandrogenic conditions.
However, despite the suggestion in the prior art that hyperandrogenic diseases are the result of a single 5.alpha.-reductase, there are reports regarding the presence of other 5.alpha.-reductase isozymes in both rats and humans. For example, in human prostate, Bruchovsky, et al. (See J. Clm. Endocrinol. Metab. 67, 806-816, 1988) and Hudson (see J. Steroid Biochem. 26, p 349-353, 1987) found different 5.alpha.-reductase activities in the stromal and epithelial fractions. Additionally, Moore and Wilson described two distinct human reductases with peaks of activities at either pH 5.5 or pH 7-9. (See J. Biol. Chem. 251, 19, p. 5895-5900, 1976.)
Recently, Andersson and Russell isolated a cDNA which encodes a rat liver 5.alpha.-reductase (see J. Biol. Chem. 264 pp. 16249-55 (1989). They found a single mRNA which encodes both the liver and prostatic reductases of rats. A sequence of this rat gene was later used to select a human prostatic cDNA encoding a 5.alpha.-reductase termed "5.alpha.-reductase 1". (See Proc. Nat'l. Acad. Sci. 87, p. 3640-3644, 1990.)
More recently, a second, more abundant reductase (5.alpha.-treductase 2) has been cloned from human prostate with properties identified with the form found in crude human prostatic extracts. (See Nature, 354, p. 159-161, 1991.)
Further, "Syndromes of Androgen Resistance"--The Biology of Reproduction, Vol. 46, p. 168-173 (1992) by Jean O. Wilson indicates that the 5.alpha.-reductase 1 enzyme is associated with hair follicles.
Thus, the art supports the existence of at least two genes for 5.alpha.-reductase and two distinct isozymes of 5.alpha.-reductase in humans. Both forms are present in
REFERENCES:
patent: 2227876 (1941-01-01), Bolt
patent: 3239417 (1966-03-01), DiTullio et al.
patent: 3264301 (1966-08-01), Doorenboos
patent: 3285918 (1966-11-01), Doorenboos et al.
patent: 4220775 (1980-09-01), Rasmusson et al.
patent: 4317817 (1982-03-01), Blohm et al.
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4596812 (1986-06-01), Chidsey, III et al.
patent: 4732897 (1988-03-01), Cainelli et al.
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 4845104 (1989-07-01), Carlin et al.
patent: 4859681 (1989-08-01), Rasmusson et al.
patent: 4882319 (1989-11-01), Holt et al.
patent: 4910226 (1990-03-01), Holt et al.
patent: 5049562 (1991-09-01), Rasmusson et al.
patent: 5110939 (1992-05-01), Holt et al.
patent: 5116983 (1992-05-01), Bhattacharya et al.
patent: 5494914 (1996-02-01), Labrie et al.
Brooks et al, Steroids, vol. 47, No. 1 (1986), "5 Alpha-reductase inhibitory . . . activities of some 4-aza-steroids in the rat", pp. 1-19.
Voight et al., Endocrinology, vol. 92 (1973), "The antiandrogenic action of 4-androsten-3-one-17beta-carboxylic acid and its methyl ester on hamster flank organ", pp. 1216-1222.
Geldof et al., Eur. J. Cancer, vol. 26, No. 2 (1990), "Enzyme inhibitors in hormone dependent prostate cancer growth", p. 188.
Kedderis et al., Toxicol. Appl. Pharmacol., vol. 93 (1988), "Studies with nitrogen-containing steroids and freshly isolated rat hepatocytes: Role of cytochrome p-450 in Detoxification", pp. 403-412.
Geldof et al., J. Cancer Res. Clin. Oncol., vol. 118 (1992), "Consideration of the use of 17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one (4MA), a 5 alpha-reductase inhibitor, in prostate cancer therapy", pp. 50-55.
The Daily (Tuesday, May 7, 1996), "New Data on Proscar, Abbott's Hytrin Show Conflicting Results".
Wall Street Journal (Tuesday, May 7, 1996), "Study Finds Abbott's Prostate Drug is Much More Effective than Merck's", p. B4.
Endo., vol. 91, No. 2, pp. 427-437 (1972) by Neri, et al., "A Biological Profile of a Non-steroidal Antiandrogen, SCH 13521 . . . ".
Steroids, 14, 269-283(1969), by Nayfeh, et al., "Metabolism of Progesterone by Rat Testicular Homogenates-III".
J. Pharm. Sci., 62, No. 4, pp. 638-640 (1973) by Doorenbos & Solomons, "Synthesis & Antimicrobial Properties of 17 Beta-Isopentyloxy-4-Aza-5 Alpha-Androstane and the 4-Methyl Derivative".
J. Pharm. Sci., 60, No. 8, pp. 1234-1235 (1971) by Doorenbos & Brown, "4.17 Alpha-Dimethyl-4-Aza-5 Alpha-Androstan-17 beta-ol Acetate & Related Azasteroids".
J. Pharm., 63, No. 4, pp. 620-622 (1974) by Doorenbos & Kim, "Synthesis & Evaluation of Antimicrobial Properties of Amidinoazaandrostanes and Guanidinoazaandrostanes".
J. Med. Chem. (1986) 29 (11): pp. 2298-3115 by Rasmusson, et al., "Aza Steroids: Structure-Activity Relationships . . . ".
The Prostate (1986) 9 (1): pp. 65-75 by Brooks, et al., "Prostatic Effects Induced in Dogs By . . . 5 alpha-Reductase Inhibitors".
Endocr. (1985) 117 (2): pp. 571-579, by Liang, et al., "Species Differences in Prostatic Steroidal 5 Alpha-Reductases of Rat, Dog and Human".
J. Med. Chem. (1984) 27 (12).sunburst. pp. 1690-1701, by Rasmusson, et al., "Azasteroids as Inhibitors of Rat Prostatic 5 alpha-reductase".
J. Org. Chem. (1981) vol. 46, No. 7, pp. 1442-1446, T. Back, et al., "N-Chloroazasteroids . . . ".
Chem. Abstracts, vol. 95, 109055j, by T. Liang, et al. "Inhibition of 5 Alpha-Receptor Binding . . . by a 4-Methyl-4-Aza-Steroid".
JNCI, vol. 74, No. 2, pp. 475-481 (Feb. 1985), by N. Kadohama, et al., "Retardation of Prostate Tumor Progression in the Noble Rat by 4-Methyl-4-Aza-Steroid Inhibitors of 5 Alpha-Reductase".
The Prostate, vol. 10, pp. 189-197 (1987) by G. Androile, et al., "The Effect of 4MA . . . on the Growth of . . . Human Tumors . . . ".
J. Endocr., vol. 57, pp. 111-121 (1973) by K. D. Bingham, et al., "The Metabolism of Testosterone by Human Male Scalp Skin".
Toxicol. Appl. Pharmacol., vol. 103, pp. 222-227 (1990) by G. L. Kedderis, et al., "Studies With Nitrogen Containing Steroids . . .
Tolman Richard L.
Witzel Bruce E.
Daus Donald G.
Fitch Catherine D.
Giesser Joanne
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reduc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reduc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reduc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-361008